By Trevor Lowenthal:
I recently conducted an email interview with Chief Operations Officer, Peter Culpepper of Provectus Pharmaceuticals (NYSEMKT:PVCT). The company operates within the biopharmaceutical industry, has roughly a $162 million market...
NEW YORK (TheStreet) --aAmpio Pharmaceuticalsa plunged to a 52-week low of $4.95 on Friday, one day after the biopharmaceutical company announced a major setback to a studyaon its osteoarthritis drug Ampion.
The company said a shipment of Ampion...
Analysts at KeyBanc downgraded Perry Ellis International (NASDAQ: PERY) from Buy to Hold and removed the target price of $20. Perry Ellis International's shares closed at $20.25 yesterday.
Canaccord Genuity downgraded Cyberonics (NASDAQ: CYBX)...
WASHINGTON (dpa-AFX) - OncoGenex Pharmaceuticals, Inc. (OGXI) Thursday said
the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small
cell lung cancer or NSCLC, is continuing as planned as per the recommendation of
NEW YORK (TheStreet) --aAmpio Pharmaceuticalsa plummeted Thursday after the company announced a major setback to a study on its osteoarthritis drug Ampion.
The company said a shipment of Ampion and a placebo was accidentally exposed to freezing...
Financial summary for the second quarter
-- Net turnover totalled SEK 564.0 million (SEK 40.7 m), of which SEK
500.7 million was contributed by royalties for simeprevir. Revenues from
By Chad Brand:
Valeant Pharmaceuticals (NYSE: VRX) might be the largest $8 billion a year (sales) specialty pharmaceutical company that people (outside of Wall Street) have never heard of. The firm has grown by leaps and bounds in recent years...
By SA Transcripts:
Hikma Pharmaceuticals Plc (OTC:HKMPF)
Q2 2014 Results Earnings Conference Call
August 20, 2014 5:30 a.m. ET
Said Darwazah - Chairman & CEO
Khalid Nabilsi - CFO
James Gordon - JP Morgan
Lannett Company, Inc. (NYSE: LCI) today announced that it has agreed to purchase ANDAs for Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg, upon the completion of a successful technical transfer. The...
Oops! Unable to complete your request. Please refresh your browser.